DORAL, Florida, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today details its branding strategy for Hygee™, a medical device designed for the detection of sexually transmitted infections (STIs) in women. With plans to market Hygee™ on five continents, ETST is deploying a striking graphic identity that will speak directly to women.

A play on the Greek word for “hygiene,” the name Hygee™ integrates intimacy, confidentiality and discretion. Hygee™ looks like - and is worn like - a standard panty liner. Aptly named, the device allows a woman to discreetly take her own sample for testing to detect STIs, starting with chlamydia.

“From the name of the device to specifics of the logo, our branding strategy reflects the personal yet crucial nature of the Hygee™ self-sampling kit. We wanted to make the brand memorable, yet simple enough to promote its ease-of-use,” states Nickolas S. Tabraue, president, director and chairman of ETST. “Hygee™ is associated with peace of mind, protection, security, health and wellness.”

The positioning of “Personal feminine health test” explains the purpose of the product. Set under the logo, it gives the target market the context needed to better understand the brand.

The tagline, “Accurate, Simple and Discreet,” reflects the personal nature of the product.

ETST CEO and Chief Science Officer Dr. Michel Aubé said, “Hygee™ is designed to preserve women’s health. Our goal is to act upstream to give women the control and the information they need to avoid severe health complications from STI.”

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/3330935c-ad09-415b-b662-94d805e17ceb

The Market

While STIs are a serious problem worldwide, the rates of infection across the USA have increased for the third consecutive year, according to the Centers for Disease Control and Prevention. The market for Hygee™ is considerable, as no one uses this technology to perform the 100 million tests for Chlamydia trachomatis done around the world each year. ETST believes Hygee™ will be an ideal tool for high throughput screening of individuals who want to know if they are infected with STIs like chlamydia and gonorrhea. It is accepted that young women are also at higher risk, and this is why ETST will market Hygee™ to target that demographic.

“The best way to fight STIs is prevention, and the only way for women to avoid the dangerous results of untreated STI is early treatment. This means that women need to know if they are infected. We believe that Hygee™ will be the best tool to provide that information. ETST will target specific populations of women globally to better counter the STI epidemic,” said Dr. Aubé.

About Earth Science Tech, Inc. (ETST)

Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.

To learn more, please visit: www.EarthScienceTech.com

ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:

Earth Science Pharmaceutical, Inc.

Earth Science Pharmaceutical ("ESP") is a wholly owned subsidiary of Earth Science Tech), committed to the development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP's CEO and chief science officer, Dr. Michel Aubé, is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com

Cannabis Therapeutics, Inc.

Cannabis Therapeutics (“CTI”) is a wholly owned subsidiary of Earth Science TechTich i poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com

KannaBidioiD, Inc.

KannaBidioiD (“KBD”) is a wholly owned subsidiary of Earth Science TechB that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com

Earth Science Foundation, Inc.

Earth Science Foundation. (“ESF”) is a wholly owned subsidiary of Earth Science Tech. ESF is in the process of becoming a nonprofit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech's effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Attachment

Company Contact:
www.EarthScienceTech.com 
Nickolas S. Tabraue
President, Director & Chairman
305.615.2118 Office

Corporate Communications Contact:
NetworkNewsWire (NNW) 
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com